147 related articles for article (PubMed ID: 11489833)
1. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.
Dardes RC; Bentrem D; O'Regan RM; Schafer JM; Jordan VC
Clin Cancer Res; 2001 Dec; 7(12):4149-55. PubMed ID: 11751515
[TBL] [Abstract][Full Text] [Related]
3. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Detre S; Riddler S; Salter J; A'Hern R; Dowsett M; Johnston SR
Cancer Res; 2003 Oct; 63(19):6516-22. PubMed ID: 14559845
[TBL] [Abstract][Full Text] [Related]
6. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
7. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
[TBL] [Abstract][Full Text] [Related]
8. A mechanism of drug resistance to tamoxifen in breast cancer.
Schafer JM; Bentrem DJ; Takei H; Gajdos C; Badve S; Jordan VC
J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):75-83. PubMed ID: 12650703
[TBL] [Abstract][Full Text] [Related]
9. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
11. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
13. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.
Gottardis MM; Jiang SY; Jeng MH; Jordan VC
Cancer Res; 1989 Aug; 49(15):4090-3. PubMed ID: 2743303
[TBL] [Abstract][Full Text] [Related]
15. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):117-27. PubMed ID: 7981452
[TBL] [Abstract][Full Text] [Related]
16. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
17. Counteraction of estradiol-induced activation of tissue-type plasminogen activator in a human breast cancer cell line by an anti-estrogen, LY117018.
Uchiumi T; Mizoguchi H; Hagino Y; Kohno K; Kuwano M
Int J Cancer; 1991 Jan; 47(1):80-5. PubMed ID: 1702405
[TBL] [Abstract][Full Text] [Related]
18. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.
Gottardis MM; Wagner RJ; Borden EC; Jordan VC
Cancer Res; 1989 Sep; 49(17):4765-9. PubMed ID: 2758410
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
[TBL] [Abstract][Full Text] [Related]
20. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.
Gottardis MM; Ricchio ME; Satyaswaroop PG; Jordan VC
Cancer Res; 1990 Jun; 50(11):3189-92. PubMed ID: 2334915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
